Surrey Heartlands

Joint Formulary & PAD

Rivastigmine - Multiple sclerosis

You are here : Home > Formulary Search > Rivastigmine - Multiple sclerosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Non Formulary
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
NFD1
Restrictions / Comments :

Documentation

Guidelines (Local)
Dementia Treatment Pathway - Feb 2019
Policy Statement
Acetylcholinesterase inhibitors and memantine for cognitive impairment in Multiple Sclerosis - Policy statement APC 395- 2019 - Mar 19

PAD Profile

ChemicalSubstance :
Rivastigmine
Indication :
Multiple sclerosis
Group Name :
Keywords :
cognitive impairment in MS
Brand Names Include :
Exelon patch, Nimvastid, Almuriva, Alzest, Prometax, Voleze
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Rivastigmine is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Multiple sclerosis.

Committee Recommendations (2)

03 Jun 20 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

At the Surrey and North-West Sussex Area Prescribing Committee (APC) held in June 2020, it was decided that all BLACK status drugs would have their review dates extended for 5 years without the need for a review.

If a clinician or provider wishes to change the traffic light status of any BLACK drug then they will need to submit a paper for change as per usual APC process.

06 Mar 19 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)

The Surrey and North West Sussex Area Prescribing Committee (APC) does not recommend AChE inhibitors* or memantine for people with cognitive impairment caused by multiple sclerosis, in line with NICE guideline (NG97)

* AChE inhibitors - donepezil, galantamine amd rivastigmine